Pub Date : 2025-02-01DOI: 10.1016/j.ajog.2024.08.008
Gabriel Levin MD , Pedro T. Ramirez MD , Jason D. Wright MD , Brian M. Slomovitz MD , Kacey M. Hamilton MD , Rebecca J. Schneyer MD , Moshe Barnajian MD , Yosef Nasseri MD , Matthew T. Siedhoff MD, MSCR , Kelly N. Wright MD , Raanan Meyer MD
<div><h3>Background</h3><div>The Laparoscopic Approach to Cervical Cancer study results revolutionized our understanding of the best surgical management for this disease. After its publication, the guidelines state that the standard and recommended approach for radical hysterectomy is an open abdominal approach. Nevertheless, the effect of the Laparoscopic Approach to Cervical Cancer trial on real-world changes in the surgical approach to radical hysterectomy remains elusive.</div></div><div><h3>Objective</h3><div>This study aimed to investigate the trends and routes of radical hysterectomy and to evaluate postoperative complication rates before and after the Laparoscopic Approach to Cervical Cancer trial (2018).</div></div><div><h3>Study Design</h3><div>The National Surgical Quality Improvement Program registry was used to examine radical hysterectomy for cervical cancer performed between 2012 and 2022. This study excluded vaginal radical hysterectomies and simple hysterectomies. The primary outcome measures were the trends in the route of surgery (minimally invasive surgery vs laparotomy) and surgical complication rates, stratified by periods before and after the publication of the Laparoscopic Approach to Cervical Cancer trial in 2018 (2012–2017 vs 2019–2022). The secondary outcome measure was major complications associated specifically with the different routes of surgery.</div></div><div><h3>Results</h3><div>Of the 3611 patients included, 2080 (57.6%) underwent laparotomy, and 1531 (42.4%) underwent minimally invasive radical hysterectomy. There was a significant increase in the minimally invasive surgery approach from 2012 to 2017 (45.6% in minimally invasive surgery in 2012 to 75.3% in minimally invasive surgery in 2017; <em>P</em><.01) and a significant decrease in minimally invasive surgery from 2018 to 2022 (50.4% in minimally invasive surgery in 2018 to 11.4% in minimally invasive surgery in 2022; <em>P</em><.001). The rate of minor complications was lower in the period before the Laparoscopic Approach to Cervical Cancer trial than after the trial (317 [16.9%] vs 288 [21.3%], respectively; <em>P</em>=.002). The major complication rates were similar before and after the Laparoscopic Approach to Cervical Cancer trial (139 [7.4%] vs 78 [5.8%], respectively; <em>P</em>=.26). The rates of blood transfusions and superficial surgical site infections were lower in the period before the Laparoscopic Approach to Cervical Cancer trial than in the period after the trial (137 [7.3%] vs 133 [9.8%] [<em>P</em>=.012] and 20 [1.1%] vs 53 [3.9%] [<em>P</em><.001], respectively). In a comparison of minimally invasive surgery vs laparotomy radical hysterectomy during the entire study period, patients in the minimally invasive surgery group had lower rates of minor complications than in those in the laparotomy group (190 [12.4%] vs 472 [22.7%], respectively; <em>P</em><.001), and the rates of major complications were similar in both groups (100
{"title":"Approach to radical hysterectomy for cervical cancer after the Laparoscopic Approach to Cervical Cancer trial and associated complications: a National Surgical Quality Improvement Program study","authors":"Gabriel Levin MD , Pedro T. Ramirez MD , Jason D. Wright MD , Brian M. Slomovitz MD , Kacey M. Hamilton MD , Rebecca J. Schneyer MD , Moshe Barnajian MD , Yosef Nasseri MD , Matthew T. Siedhoff MD, MSCR , Kelly N. Wright MD , Raanan Meyer MD","doi":"10.1016/j.ajog.2024.08.008","DOIUrl":"10.1016/j.ajog.2024.08.008","url":null,"abstract":"<div><h3>Background</h3><div>The Laparoscopic Approach to Cervical Cancer study results revolutionized our understanding of the best surgical management for this disease. After its publication, the guidelines state that the standard and recommended approach for radical hysterectomy is an open abdominal approach. Nevertheless, the effect of the Laparoscopic Approach to Cervical Cancer trial on real-world changes in the surgical approach to radical hysterectomy remains elusive.</div></div><div><h3>Objective</h3><div>This study aimed to investigate the trends and routes of radical hysterectomy and to evaluate postoperative complication rates before and after the Laparoscopic Approach to Cervical Cancer trial (2018).</div></div><div><h3>Study Design</h3><div>The National Surgical Quality Improvement Program registry was used to examine radical hysterectomy for cervical cancer performed between 2012 and 2022. This study excluded vaginal radical hysterectomies and simple hysterectomies. The primary outcome measures were the trends in the route of surgery (minimally invasive surgery vs laparotomy) and surgical complication rates, stratified by periods before and after the publication of the Laparoscopic Approach to Cervical Cancer trial in 2018 (2012–2017 vs 2019–2022). The secondary outcome measure was major complications associated specifically with the different routes of surgery.</div></div><div><h3>Results</h3><div>Of the 3611 patients included, 2080 (57.6%) underwent laparotomy, and 1531 (42.4%) underwent minimally invasive radical hysterectomy. There was a significant increase in the minimally invasive surgery approach from 2012 to 2017 (45.6% in minimally invasive surgery in 2012 to 75.3% in minimally invasive surgery in 2017; <em>P</em><.01) and a significant decrease in minimally invasive surgery from 2018 to 2022 (50.4% in minimally invasive surgery in 2018 to 11.4% in minimally invasive surgery in 2022; <em>P</em><.001). The rate of minor complications was lower in the period before the Laparoscopic Approach to Cervical Cancer trial than after the trial (317 [16.9%] vs 288 [21.3%], respectively; <em>P</em>=.002). The major complication rates were similar before and after the Laparoscopic Approach to Cervical Cancer trial (139 [7.4%] vs 78 [5.8%], respectively; <em>P</em>=.26). The rates of blood transfusions and superficial surgical site infections were lower in the period before the Laparoscopic Approach to Cervical Cancer trial than in the period after the trial (137 [7.3%] vs 133 [9.8%] [<em>P</em>=.012] and 20 [1.1%] vs 53 [3.9%] [<em>P</em><.001], respectively). In a comparison of minimally invasive surgery vs laparotomy radical hysterectomy during the entire study period, patients in the minimally invasive surgery group had lower rates of minor complications than in those in the laparotomy group (190 [12.4%] vs 472 [22.7%], respectively; <em>P</em><.001), and the rates of major complications were similar in both groups (100","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":"232 2","pages":"Pages 208.e1-208.e11"},"PeriodicalIF":8.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Endometriosis of the Bartholin gland in a patient with deep endometriosis","authors":"Sebastián Lavanderos MD , Valeria Puebla MD , Osman Barboza MD","doi":"10.1016/j.ajog.2024.09.104","DOIUrl":"10.1016/j.ajog.2024.09.104","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":"232 2","pages":"Pages 232-234"},"PeriodicalIF":8.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142363971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajog.2024.07.032
Jianfang Liao MD, Juan Cao MD
{"title":"Agnostic identification of plasma biomarkers","authors":"Jianfang Liao MD, Juan Cao MD","doi":"10.1016/j.ajog.2024.07.032","DOIUrl":"10.1016/j.ajog.2024.07.032","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":"232 2","pages":"Page e49"},"PeriodicalIF":8.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141791666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajog.2024.05.012
Joyce E.M. Van Der Heijden MSc , Hedwig Van Hove MSc , Niki M. Van Elst BSc , Petra Van Den Broek BSc , Joris Van Drongelen MD, PhD , Hubertina C.J. Scheepers MD, PhD , Saskia N. De Wildt MD, PhD , Rick Greupink PharmD, PhD
Background
Antenatal betamethasone and dexamethasone are prescribed to women who are at high risk of premature birth to prevent neonatal respiratory distress syndrome (RDS). The current treatment regimens, effective to prevent neonatal RDS, may be suboptimal. Recently, concerns have been raised regarding possible adverse long-term neurological outcomes due to high fetal drug exposures. Data from nonhuman primates and sheep suggest maintaining a fetal plasma concentration above 1 ng/mL for 48 hours to retain efficacy, while avoiding undesirable high fetal plasma levels.
Objective
We aimed to re-evaluate the current betamethasone and dexamethasone dosing strategies to assess estimated fetal exposure and provide new dosing proposals that meet the efficacy target but avoid excessive peak exposures.
Study design
A pregnancy physiologically based pharmacokinetic (PBPK) model was used to predict fetal drug exposures. To allow prediction of the extent of betamethasone and dexamethasone exposure in the fetus, placenta perfusion experiments were conducted to determine placental transfer. Placental transfer rates were integrated in the PBPK model to predict fetal exposure and model performance was verified using published maternal and fetal pharmacokinetic data. The verified pregnancy PBPK models were then used to simulate alternative dosing regimens to establish a model-informed dose.
Results
Ex vivo data showed that both drugs extensively cross the placenta. For betamethasone 15.7±1.7% and for dexamethasone 14.4±1.5%, the initial maternal perfusate concentration reached the fetal circulations at the end of the 3-hour perfusion period. Pregnancy PBPK models that include these ex vivo-derived placental transfer rates accurately predicted maternal and fetal exposures resulting from current dosing regimens. The dose simulations suggest that for betamethasone intramuscular, a dose reduction from 2 dosages 11.4 mg, 24 hours apart, to 4 dosages 1.425 mg, 12 hours apart would avoid excessive peak exposures and still meet the fetal response threshold. For dexamethasone, the dose may be reduced from 4 times 6 mg every 12 hours to 8 times 1.5 mg every 6 hours.
Conclusion
A combined placenta perfusion and pregnancy PBPK modeling approach adequately predicted both maternal and fetal drug exposures of 2 antenatal corticosteroids (ACSs). Strikingly, our PBPK simulations suggest that drug doses might be reduced drastically to still meet earlier proposed efficacy targets and minimize peak exposures. We propose the provided model-informed dosing regimens are used to support further discussion on an updated ACS scheme and design of clinical trials to confirm the effectiveness and safety of lower doses.
{"title":"Optimization of the betamethasone and dexamethasone dosing regimen during pregnancy: a combined placenta perfusion and pregnancy physiologically based pharmacokinetic modeling approach","authors":"Joyce E.M. Van Der Heijden MSc , Hedwig Van Hove MSc , Niki M. Van Elst BSc , Petra Van Den Broek BSc , Joris Van Drongelen MD, PhD , Hubertina C.J. Scheepers MD, PhD , Saskia N. De Wildt MD, PhD , Rick Greupink PharmD, PhD","doi":"10.1016/j.ajog.2024.05.012","DOIUrl":"10.1016/j.ajog.2024.05.012","url":null,"abstract":"<div><h3>Background</h3><div>Antenatal betamethasone and dexamethasone are prescribed to women who are at high risk of premature birth to prevent neonatal respiratory distress syndrome (RDS). The current treatment regimens, effective to prevent neonatal RDS, may be suboptimal. Recently, concerns have been raised regarding possible adverse long-term neurological outcomes due to high fetal drug exposures. Data from nonhuman primates and sheep suggest maintaining a fetal plasma concentration above 1 ng/mL for 48 hours to retain efficacy, while avoiding undesirable high fetal plasma levels.</div></div><div><h3>Objective</h3><div>We aimed to re-evaluate the current betamethasone and dexamethasone dosing strategies to assess estimated fetal exposure and provide new dosing proposals that meet the efficacy target but avoid excessive peak exposures.</div></div><div><h3>Study design</h3><div>A pregnancy physiologically based pharmacokinetic (PBPK) model was used to predict fetal drug exposures. To allow prediction of the extent of betamethasone and dexamethasone exposure in the fetus, placenta perfusion experiments were conducted to determine placental transfer. Placental transfer rates were integrated in the PBPK model to predict fetal exposure and model performance was verified using published maternal and fetal pharmacokinetic data. The verified pregnancy PBPK models were then used to simulate alternative dosing regimens to establish a model-informed dose.</div></div><div><h3>Results</h3><div>Ex vivo data showed that both drugs extensively cross the placenta. For betamethasone 15.7±1.7% and for dexamethasone 14.4±1.5%, the initial maternal perfusate concentration reached the fetal circulations at the end of the 3-hour perfusion period. Pregnancy PBPK models that include these ex vivo-derived placental transfer rates accurately predicted maternal and fetal exposures resulting from current dosing regimens. The dose simulations suggest that for betamethasone intramuscular, a dose reduction from 2 dosages 11.4 mg, 24 hours apart, to 4 dosages 1.425 mg, 12 hours apart would avoid excessive peak exposures and still meet the fetal response threshold. For dexamethasone, the dose may be reduced from 4 times 6 mg every 12 hours to 8 times 1.5 mg every 6 hours.</div></div><div><h3>Conclusion</h3><div>A combined placenta perfusion and pregnancy PBPK modeling approach adequately predicted both maternal and fetal drug exposures of 2 antenatal corticosteroids (ACSs). Strikingly, our PBPK simulations suggest that drug doses might be reduced drastically to still meet earlier proposed efficacy targets and minimize peak exposures. We propose the provided model-informed dosing regimens are used to support further discussion on an updated ACS scheme and design of clinical trials to confirm the effectiveness and safety of lower doses.</div></div>","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":"232 2","pages":"Pages 228.e1-228.e9"},"PeriodicalIF":8.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141040285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajog.2024.10.032
Elizabeth J. Suh-Burgmann MD, Holly Finertie MPH, Nickolas Nguyen, Sarah Dolisca MD, Julie A. Schmittdiel PhD
{"title":"Detection of endometrial cancer-related bleeding in virtual visits","authors":"Elizabeth J. Suh-Burgmann MD, Holly Finertie MPH, Nickolas Nguyen, Sarah Dolisca MD, Julie A. Schmittdiel PhD","doi":"10.1016/j.ajog.2024.10.032","DOIUrl":"10.1016/j.ajog.2024.10.032","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":"232 2","pages":"Pages e40-e44"},"PeriodicalIF":8.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142556915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajog.2024.04.032
Laura J. Slade , Argyro Syngelaki PhD , Milly Wilson MWH , Hiten D. Mistry PhD , Ranjit Akolekar MD , Peter von Dadelszen PhD , Kypros H. Nicolaides MD , Laura A. Magee MD
<div><h3>Background</h3><div><span>A parallel has been drawn between first-trimester placental vascular maturation and maternal cardiovascular adaptations, including blood pressure. Although 140/90 mm Hg is well-accepted as the threshold for chronic hypertension in the general obstetric population in early pregnancy, a different threshold could apply to stratify the risk of </span>adverse outcomes<span><span>, such as preeclampsia. This could have implications for interventions, such as the threshold for initiation of </span>antihypertensive therapy and the target blood pressure level.</span></div></div><div><h3>Objective</h3><div><span>We evaluated the relationship between various blood pressure cutoffs at 11–13 weeks of gestation and the development of </span>preeclampsia, overall and according to key maternal characteristics.</div></div><div><h3>Study Design</h3><div><span><span><span>This secondary analysis was of data from a prospective nonintervention cohort study of singleton pregnancies delivering at ≥24 weeks, without major anomalies, at 2 United Kingdom maternity hospitals, 2006–2020. Blood pressure at 11–13 weeks of gestation was classified according to American College of Cardiology/American Heart Association categories (mm Hg) as (1) normal blood pressure (systolic <120 and diastolic <80), (2) </span>elevated blood pressure<span> (systolic ≥120 and diastolic <80), stage 1 hypertension (systolic ≥130 or diastolic 80–89), and stage 2 hypertension (systolic ≥140 or diastolic ≥90). For blood pressure category thresholds and the outcome of preeclampsia, the following were calculated overall and across maternal age, </span></span>body mass index, ethnicity, method of conception, and previous pregnancy history: detection rate, screen-positive rate, and positive and negative likelihood ratios, with 95% confidence intervals. A </span><em>P</em> value of <.05 was considered significant.</div></div><div><h3>Results</h3><div><span><span>There were 137,458 pregnancies screened at 11–13 weeks of gestation. The population was ethnically diverse, with 15.9% of Black ethnicity, 6.7% of South or East Asian ethnicity, and 2.7% of mixed ethnicity, with the remainder of White ethnicity. Compared with normal blood pressure, stage 2 hypertension was associated with both preterm preeclampsia (0.3% to 4.9%) and term preeclampsia (1.0% to 8.3%). A blood pressure threshold of 140/90 mm Hg was good at identifying women at increased risk of preeclampsia overall (positive likelihood ratio, 5.61 [95% confidence interval, 5.14–6.11]) and across maternal characteristics, compared with elevated blood pressure (positive likelihood ratio, 1.70 [95% confidence interval, 1.63–1.77]) and stage 1 hypertension (positive likelihood ratio, 2.68 [95% confidence interval, 2.58–2.77]). There were 2 exceptions: a blood pressure threshold of 130/80 mm Hg was better for the 2.1% of women with </span>body mass index <18.5 kg/m</span><sup>2</sup><span> (positive likeli
{"title":"Blood pressure cutoffs at 11-13 weeks of gestation and risk of preeclampsia","authors":"Laura J. Slade , Argyro Syngelaki PhD , Milly Wilson MWH , Hiten D. Mistry PhD , Ranjit Akolekar MD , Peter von Dadelszen PhD , Kypros H. Nicolaides MD , Laura A. Magee MD","doi":"10.1016/j.ajog.2024.04.032","DOIUrl":"10.1016/j.ajog.2024.04.032","url":null,"abstract":"<div><h3>Background</h3><div><span>A parallel has been drawn between first-trimester placental vascular maturation and maternal cardiovascular adaptations, including blood pressure. Although 140/90 mm Hg is well-accepted as the threshold for chronic hypertension in the general obstetric population in early pregnancy, a different threshold could apply to stratify the risk of </span>adverse outcomes<span><span>, such as preeclampsia. This could have implications for interventions, such as the threshold for initiation of </span>antihypertensive therapy and the target blood pressure level.</span></div></div><div><h3>Objective</h3><div><span>We evaluated the relationship between various blood pressure cutoffs at 11–13 weeks of gestation and the development of </span>preeclampsia, overall and according to key maternal characteristics.</div></div><div><h3>Study Design</h3><div><span><span><span>This secondary analysis was of data from a prospective nonintervention cohort study of singleton pregnancies delivering at ≥24 weeks, without major anomalies, at 2 United Kingdom maternity hospitals, 2006–2020. Blood pressure at 11–13 weeks of gestation was classified according to American College of Cardiology/American Heart Association categories (mm Hg) as (1) normal blood pressure (systolic <120 and diastolic <80), (2) </span>elevated blood pressure<span> (systolic ≥120 and diastolic <80), stage 1 hypertension (systolic ≥130 or diastolic 80–89), and stage 2 hypertension (systolic ≥140 or diastolic ≥90). For blood pressure category thresholds and the outcome of preeclampsia, the following were calculated overall and across maternal age, </span></span>body mass index, ethnicity, method of conception, and previous pregnancy history: detection rate, screen-positive rate, and positive and negative likelihood ratios, with 95% confidence intervals. A </span><em>P</em> value of <.05 was considered significant.</div></div><div><h3>Results</h3><div><span><span>There were 137,458 pregnancies screened at 11–13 weeks of gestation. The population was ethnically diverse, with 15.9% of Black ethnicity, 6.7% of South or East Asian ethnicity, and 2.7% of mixed ethnicity, with the remainder of White ethnicity. Compared with normal blood pressure, stage 2 hypertension was associated with both preterm preeclampsia (0.3% to 4.9%) and term preeclampsia (1.0% to 8.3%). A blood pressure threshold of 140/90 mm Hg was good at identifying women at increased risk of preeclampsia overall (positive likelihood ratio, 5.61 [95% confidence interval, 5.14–6.11]) and across maternal characteristics, compared with elevated blood pressure (positive likelihood ratio, 1.70 [95% confidence interval, 1.63–1.77]) and stage 1 hypertension (positive likelihood ratio, 2.68 [95% confidence interval, 2.58–2.77]). There were 2 exceptions: a blood pressure threshold of 130/80 mm Hg was better for the 2.1% of women with </span>body mass index <18.5 kg/m</span><sup>2</sup><span> (positive likeli","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":"232 2","pages":"Pages 214.e1-214.e10"},"PeriodicalIF":8.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140850066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajog.2024.07.037
Jennifer A. McCoy MD, MSCE, William G. La Cava PhD
{"title":"Deep learning to predict fetal acidemia: a response","authors":"Jennifer A. McCoy MD, MSCE, William G. La Cava PhD","doi":"10.1016/j.ajog.2024.07.037","DOIUrl":"10.1016/j.ajog.2024.07.037","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":"232 2","pages":"Page e46"},"PeriodicalIF":8.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141791669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajog.2024.09.017
Albaro J. Nieto-Calvache MD , Jose M. Palacios-Jaraquemada MD, PhD , Rozi A. Aryananda MD , Nicolas Basanta MD , Nareswari Cininta MD , Luisa F. Rivera-Torres MD , Esperanza Bautista MD , Ahmed M. Hussein MD
{"title":"External aortic compression: buying time to save lives in obstetric hemorrhage","authors":"Albaro J. Nieto-Calvache MD , Jose M. Palacios-Jaraquemada MD, PhD , Rozi A. Aryananda MD , Nicolas Basanta MD , Nareswari Cininta MD , Luisa F. Rivera-Torres MD , Esperanza Bautista MD , Ahmed M. Hussein MD","doi":"10.1016/j.ajog.2024.09.017","DOIUrl":"10.1016/j.ajog.2024.09.017","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":"232 2","pages":"Pages 239-241"},"PeriodicalIF":8.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajog.2024.09.008
Sarosh Rana MD, MPH, Luke P. Burns MD
{"title":"Real-world evidence for utility of serum angiogenic and antiangiogenic biomarker testing","authors":"Sarosh Rana MD, MPH, Luke P. Burns MD","doi":"10.1016/j.ajog.2024.09.008","DOIUrl":"10.1016/j.ajog.2024.09.008","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":"232 2","pages":"Page e71"},"PeriodicalIF":8.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：